98 results
8-K
EX-99.1
gyajwji5k icmv
29 Aug 23
FibroGen Announces Topline Results from LELANTOS-2, a Phase 3 Clinical Study of Pamrevlumab in Ambulatory Duchenne Muscular Dystrophy
5:14pm
8-K
kkey04vfm
19 Jul 23
Cost Associated with Exit or Disposal Activities
7:01am
8-K
EX-99.1
uywrzyq4brprrypxp
26 Jun 23
FibroGen Announces Topline Results from Phase 3 ZEPHYRUS-1 Study of Pamrevlumab for the Treatment of Idiopathic Pulmonary Fibrosis
9:05am
8-K
EX-99.1
lscye4x 88
7 Jun 23
FibroGen Announces Topline Results from LELANTOS-1 Phase 3 Clinical Study of Pamrevlumab in Non-Ambulatory Patients with Duchenne Muscular Dystrophy
9:00am
DEFA14A
25zbub 0ufflc5sye0a
31 May 23
Additional proxy soliciting materials
9:00am
8-K
83b0w62405o ib
1 May 23
Entry into a Material Definitive Agreement
4:48pm
S-3ASR
bpido2
8 Aug 22
Automatic shelf registration
5:12pm